GU Cancers 2024 | The role of machine learning in predicting avelumab efficacy in LA/mUC

Patrizia Giannatempo, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, comments on results from a real-world study using machine learning to predict response and progression-free survival (PFS) in patients with locally advanced/metastatic urothelial carcinoma (LA/mUC) treated with avelumab. Promising efficacy predictions were made, highlighting the importance of specific features for overall response rate (ORR) and progression-free survival (PFS). This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.